Literature DB >> 16150960

Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference.

Keith H Nuechterlein1, Trevor W Robbins, Haim Einat.   

Abstract

At the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) New Approaches Conference, a discussion group focused on directions for future research that are critical to enhancing our understanding of the distinctions among key cognitive domains that have relevance for the development of cognition-enhancing interventions. One set of recommendations emphasizes the need for examining and optimizing the psychometric properties of relevant measurement paradigms from cognitive psychology and cognitive neuroscience. This step is critical to translating many notable advances in these basic fields into measures that would be appropriate for clinical trials. A second set of recommendations focuses on key directions for the development and application of animal models of cognitive processes that would greatly aid the discovery and preclinical testing of potential cognition-enhancing agents. As part of this process, the group noted several existing animal paradigms that have particular promise as measures in the key cognitive domains in schizophrenia identified by the MATRICS Neurocognition Committee.

Entities:  

Mesh:

Year:  2005        PMID: 16150960     DOI: 10.1093/schbul/sbi047

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  18 in total

1.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

2.  Anticipating DSM-V: opportunities and challenges for cognition and psychosis.

Authors:  Deanna M Barch; Richard S E Keefe
Journal:  Schizophr Bull       Date:  2009-11-18       Impact factor: 9.306

3.  Sustained attention in mice: expanding the translational utility of the SAT by incorporating the Michigan Controlled Access Response Port (MICARP).

Authors:  Megan St Peters; Ajeesh Koshy Cherian; Marc Bradshaw; Martin Sarter
Journal:  Behav Brain Res       Date:  2011-08-22       Impact factor: 3.332

Review 4.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 5.  Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment.

Authors:  Louis S Matza; Robert Buchanan; Scot Purdon; Jessica Brewster-Jordan; Yang Zhao; Dennis A Revicki
Journal:  Schizophr Bull       Date:  2006-07-07       Impact factor: 9.306

Review 6.  Promise and pitfalls of animal models of schizophrenia.

Authors:  David Feifel; Paul D Shilling
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

7.  A qualitative assessment of cross-cultural adaptation of intermediate measures for schizophrenia in multisite international studies.

Authors:  Jodi M Gonzalez; Maureen Rubin; Megan M Fredrick; Dawn I Velligan
Journal:  Psychiatry Res       Date:  2012-11-17       Impact factor: 3.222

Review 8.  Cognition in mouse models of schizophrenia susceptibility genes.

Authors:  P Alexander Arguello; Joseph A Gogos
Journal:  Schizophr Bull       Date:  2009-12-21       Impact factor: 9.306

9.  Nonsocial and social cognition in schizophrenia: current evidence and future directions.

Authors:  Michael F Green; William P Horan; Junghee Lee
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

10.  The reliability and validity of the MATRICS functional assessment battery.

Authors:  Dawn I Velligan; Megan Fredrick; Jim Mintz; Xueying Li; Maureen Rubin; Sanjay Dube; Smita N Deshpande; Jitendra K Trivedi; Shiv Gautam; Ajit Avasthi; Robert S Kern; Stephen R Marder
Journal:  Schizophr Bull       Date:  2013-11-09       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.